Novel Detection and Progression Markers for Diabetes Based on Continuous Glucose Monitoring Data Dynamics
Authors' conclusion
CGM dynamics markers can be an alternative to fasting plasma glucose or glucose tolerance testing to identify individuals at higher immunological risk of progressing to type 1 diabetes.
Study context
- Population
- Individuals with T1D, T2D, or healthy individuals with or without islet autoantibody status; 5754 daily continuous glucose monitoring (CGM) profiles5,754 daily CGM profiles
- Participants
- 843 individuals
- Comparison
- CGM entropy rate (ER) vs Poincaré plot ellipse area (S) for discriminating health vs diabetes, T1D vs T2D, and low vs high T1D immunological risk
- Outcome
- Discriminative power (AUC) of ER and S at Youden-index optimal cut-points
Performance
As reported in the abstract
Case 1: health vs diabetes
| Test or model | AUC | Cutoff |
|---|---|---|
| ER | 0.98 (95% CI, 0.97-0.99) | 0.76 BPT |
| S | 0.99 (95% CI, 0.99-1.00) | 1993.91 mg2/dL2 |
AUC
ER0.98 (95% CI, 0.97-0.99)
S0.99 (95% CI, 0.99-1.00)
Cutoff
ER0.76 BPT
S1993.91 mg2/dL2
Further findings
| Outcome | ER | S |
|---|---|---|
| Case 2: T1D vs T2D | ||
| AUC | 0.81 (95% CI, 0.77-0.84) | 0.76 (95% CI, 0.72-0.81) |
| Cutoff | 1.00 BPT | 5112.98 mg2/dL2 |
| Case 3: low vs high T1D immunological risk | ||
| AUC | 0.72 (95% CI, 0.58-0.86) | 0.66 (95% CI, 0.47-0.86) |
| Cutoff | 0.52 BPT | 923.65 mg2/dL2 |
Original publication
Novel Detection and Progression Markers for Diabetes Based on Continuous Glucose Monitoring Data Dynamics. J Clin Endocrinol Metab. Published 31 May 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →